Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma

Journal of Urology

Volumn 155, Issue 4, 1996, Pages 1340-1343

  Cussenot, O ^a   Villette, J M ^a   Valeri, A ^a   Cariou, G ^a   Desgrandchamps, F ^a   Cortesse, A ^a   Meria, P ^a   Teillac, P ^a   Fiet, J ^a   Le Duc, A ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

chromogranins; neuroendocrine tumors; phosphopyruvate hydratase; prostatic neoplasms

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BOMBESIN; CALCITONIN; CHROMOGRANIN A; NEURON SPECIFIC ENOLASE; NEUROPEPTIDE; NEUROTENSIN; PROSTATE SPECIFIC ANTIGEN; SOMATOSTATIN; SUBSTANCE P; TUMOR MARKER;

ACID PHOSPHATASE BLOOD LEVEL; ADULT; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; SURVIVAL;

EID: 9044235581     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)66261-X     Document Type: Article

References (20)

1. Di Sant'Agnese, P. A. and de Mesy Jensen, K. L.: Neuroendocrine differentiation in prostatic carcinoma. Hum. Path., 18: 849, 1987.
2. Abrahamsson, P. A., Alumets, J., Wadström, L. B., Falkmer, S. and Grimelius, L.: Peptide hormones, serotonin, and other cell differentiation markers in benign hyperplasia and in carcinoma of the prostate. Prog. Clin. Biol. Res., 243A: 489, 1987.
3. Abrahamsson, P. A., Wadström, L. B., Alumets, J., Falkmer, S. and Grimelius, L.: Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate. Path. Res. Pract., 182: 298, 1987.
4. Ohtake, R.: Four putative neuropeptides concentrations in the human urogenital tract. Comparison of the neuropeptides concentration between malignant and benign tissues. Nippon Naibunpi Gakkai Zasshi, 65: 1105, 1989.
5. Di Sant'Agnese, P. A., De Mesy Jensen, K. L. and Ackroyd, R. K.: Calcitonin, katacalcin and calcitonin gene-related peptide in the human prostate. An immunocytochemical and immunoelectron microscopic study. Arch. Path. Lab. Med., 113: 790, 1989.
6. Sasaki, A. and Yoshinaga, K.: Immunoreactive somatostatin in male reproductive system in humans. J. Clin. Endocr. Metab., 68: 996, 1989.
7. Bologna, M., Festuccia, C., Muzi, P., Biordi, L. and Ciomei, M.: Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer, 63: 1714, 1989.
8. Pinski, J., Schally, A. V., Halmos, G. and Szepeshazi, K.: Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Int. J. Cancer, 55: 963, 1993.
9. Cohen, R. J., Glezerson, G., Haffejee, Z. and Afrika, D.: Prostatic carcinoma: histological and immunohistological factors affecting prognosis. Brit. J. Urol., 66: 405, 1990.
10. Cohen, M. K., Arber, D. A., Coffield, K. S., Keegan, G. T., McClintock, J. and Speights, V. O., Jr.: Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression. Cancer, 74: 1899, 1994.
11. Logothetis, C. and Hoosein, N.: The inhibition of the paracrine progression of prostatic cancer as an approach to early therapy of prostatic carcinoma. J. Cell. Biochem., suppl., 16H: 128, 1992.
12. Di Sant'Agnese, P. A.: Neuroendocrine differentiation in human prostatic carcinoma. Hum. Path., 23: 287, 1992.
13. Falkmer, S., Askensten, U. and Nesland, J. M.: Tumour pathology of the neuron-paraneuron system and its evolutionary background, with special attention to neuro-endocrine differentiation in prostate and mammary carcinomas. Arch. Histol. Cytol., suppl., 52: 225, 1989.
14. Aprikian, A. G., Cordon-Cardo, C., Fair, W. R., Zhang, Z.-F., Bazinet, M., Hamdy, S. M. and Reuter, V. E.: Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J. Urol., 151: 914, 1994.
15. Cussenot, O., Duet, M., Cariou, G., Benelhadj, S., Desgrandchamps, F., Meria, P., Cortesse, A., Teillac, P., Le Due, A. and Mundler, O.: Apport de la scintigraphie à l'Octreoscan® dans la detection des localisations métastatiques des adénocarcinomes prostatiques. Prog. Urol., 4: B34, 1994.
16. Schally, A. V. and Redding, T. W.: Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostatic cancer. Proc. Natl. Acad. Sci., 84: 7275, 1987.
17. Kadmon, D., Thompson, T. C., Lynch, G. R. and Scardino, P. T.: Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J. Urol., 146: 358, 1991.
18. Tarle, M. and Rados, N.: Investigation on serum neurone-specific enolase in prostatic cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay. Prostate, 19: 23, 1991.
19. Cockett, A. T. K., Di Sant'Agnese, P. A., Gopinath, P., Schoen, S. and Abrahamsson, P. A.: Relationship of neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Urology, 42: 512, 1993.
20. Di Sant'Agnese, P. A. and Cockett, A. T. K: The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research. J. Urol., part 2, 152: 1927, 1994.